Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial

Core Viewpoint - The company indicated that the data supports further development of the drug for chronic weight management, either as a standalone treatment or in combination with other drugs due to its tolerability [1] Group 1 - The drug shows potential for chronic weight management [1] - The tolerability of the drug is a key factor in its further development [1] - The company is exploring both standalone and combination treatment options [1]